CN106344784A - Composition with functions of losing weight and enhancing immunity and preparation method thereof - Google Patents
Composition with functions of losing weight and enhancing immunity and preparation method thereof Download PDFInfo
- Publication number
- CN106344784A CN106344784A CN201610729715.XA CN201610729715A CN106344784A CN 106344784 A CN106344784 A CN 106344784A CN 201610729715 A CN201610729715 A CN 201610729715A CN 106344784 A CN106344784 A CN 106344784A
- Authority
- CN
- China
- Prior art keywords
- compositionss
- fat
- parts
- bulbus fritillariae
- enhancing immunity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 230000036039 immunity Effects 0.000 title claims abstract description 37
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000006870 function Effects 0.000 title abstract description 7
- 235000013557 nattō Nutrition 0.000 claims abstract description 49
- 239000000843 powder Substances 0.000 claims abstract description 49
- 239000002994 raw material Substances 0.000 claims abstract description 18
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 90
- 239000008176 lyophilized powder Substances 0.000 claims description 46
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 45
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 45
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 28
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 22
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 19
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 19
- 239000000377 silicon dioxide Substances 0.000 claims description 19
- 235000012239 silicon dioxide Nutrition 0.000 claims description 19
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 2
- 241001547127 Fritillaria cirrhosa Species 0.000 abstract 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 239000000725 suspension Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 11
- 238000003304 gavage Methods 0.000 description 11
- 239000013642 negative control Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 8
- 230000000242 pagocytic effect Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 229940116364 hard fat Drugs 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000976 ink Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 235000019737 Animal fat Nutrition 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186016 Bifidobacterium bifidum Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001644290 Fritillaria unibracteata Species 0.000 description 1
- 241001209916 Fritillaria unibracteata var. wabuensis Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037205 Sal-like protein 2 Human genes 0.000 description 1
- 101710192308 Sal-like protein 2 Proteins 0.000 description 1
- 239000000877 Sex Attractant Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a composition with functions of losing weight and enhancing immunity. The composition is prepared from natto freeze-dried powder, xylooligosaccharide and fritillaria cirrhosa according to a certain weight ratio by a certain preparation method. The animal experiment indicates that the composition can effectively lower the weight, reduce the fat quantity and enhance the immunity of organisms. The composition has the advantages of refined raw material selection, reasonable formula and simple preparation method, and is safe and effective.
Description
Technical field
The present invention relates to medicine and field of health care food, more particularly, to a kind of group with fat-reducing and enhancing immunity effect
Compound and preparation method thereof.
Background technology
Immunity is a kind of special protectiveness physiological function of body.By immunity, body is capable of identify that " self ", exclusion
" dissident ", to maintain the balance of interior environment and to stablize.In people in life, immunity all the time with infectious disease, non-infectious
The aging course of disease, tumor and body contends with.Immunity is the defense mechanism of human body itself, is human bioequivalence and elimination
Any foreign body (virus, antibacterial etc.) of external intrusion；Process aging, damage, the dead, own cells of degeneration and identification and place
Reason vivo mutations cell and the ability of virus infected cell.Immunocompromised person, because self immune system can not effectively be defendd
Sex pheromone is invaded and is removed itself mutant cell, easily infection and disease.
Hypoimmunity can also lead to obesity simultaneously.Obesity is not singly the sign of body shape changes, and it can also increase related disease
Disease as hypertension, arteriosclerosis, cerebrovas-cularaccident, Anomalous lipid metablism, type 2 diabetes mellitus, gout, sleep apnea, cholecystitis,
The M ＆ M of cholelithiasis, arthritis and some cancers.Therefore, prevent and treat fat, enhancing human body immunity power, safeguard body
Body health is most important.
Content of the invention
For above-mentioned situation, the present invention will provide a kind of compositionss with fat-reducing and enhancing immunity effect, this combination
Thing scientific formula, formula are proper, can reduce body weight, reduce fat mass, improve immunity of organisms, taking convenience, safely and effectively.
It is a further object to provide a kind of preparation side of the compositionss with fat-reducing and enhancing immunity effect
Method.
It is a still further object of the present invention to provide said composition preparation fat-reducing and the food of enhancing immunity, health product or
Purposes in medicine.
A kind of heretofore described compositionss, the raw material of said composition and weight with fat-reducing and enhancing immunity effect
Proportioning is: 10～30 parts of natto lyophilized powder, 10～30 parts of oligomeric xylose, 5～15 parts of Bulbus Fritillariae Cirrhosae.
Preferably, described a kind of compositionss, the raw material of said composition and weight with fat-reducing and enhancing immunity effect
Proportioning is: the raw material of described compositionss and weight proportion are: 15～25 parts of natto lyophilized powder, 10～20 parts of oligomeric xylose, Bulbus Fritillariae Cirrhosae
Female 5～12 parts.
It is further preferred that a kind of described compositionss with fat-reducing and enhancing immunity effect, the raw material of said composition
And weight proportion is: the raw material of described compositionss and weight proportion are: 17～22 parts of natto lyophilized powder, oligomeric xylose 13～19
Part, 5～10 parts of Bulbus Fritillariae Cirrhosae.
It is further preferred that described a kind of have fat-reducing and enhancing immunity effect compositionss, the raw material of said composition and
Weight proportion is: the raw material of described compositionss and weight proportion are: 18 parts of natto lyophilized powder, 18 parts of oligomeric xylose, Bulbus Fritillariae Cirrhosae 9
Part.
The present composition is using above-mentioned raw materials medicine, adds pharmaceutically acceptable adjuvant, conventionally, preparation
Preparation.
Preferably, described preparation is broken into fine powder for Bulbus Fritillariae Cirrhosae powder, and natto lyophilized powder, oligomeric xylose are directly used as medicine and make.
It is further preferred that described preparation is oral formulations.
It is further preferred that described preparation is granule, tablet, mixture, capsule.
Present invention also offers the preparation method of said composition, comprise the steps: to weigh by weight natto lyophilized powder,
Oligomeric xylose, Bulbus Fritillariae Cirrhosae；Bulbus Fritillariae Cirrhosae is pulverized and sieved, obtains Bulbus Fritillariae Cirrhosae fine powder；Natto lyophilized powder, oligomeric xylose are sieved respectively,
Obtain natto lyophilized powder fine powder and oligomeric xylose fine powder；Weigh 7～12 parts of Microcrystalline Cellulose, 0.1～0.5 part of magnesium stearate, 0.1～
0.8 part of silicon dioxide crosses 80 mesh sieves respectively, standby；By Bulbus Fritillariae Cirrhosae fine powder, natto lyophilized powder fine powder, oligomeric xylose fine powder and sieve
Microcrystalline Cellulose afterwards, magnesium stearate, silicon dioxide mix homogeneously, tabletting, prepared tablet.
Present invention also offers use in food, health product or the medicine preparing fat-reducing and enhancing immunity for the said composition
On the way.
The Bulbus Fritillariae Cirrhosae that the present invention is previously mentioned is liliaceous plant Bulbus Fritillariae Cirrhosae, Fritillaria unibracteata, Gansu Bulbus Fritillariae Uninbracteatae, Bulbus Fritillariae cirrhosae, too
The dry bulb of white Bulbus Fritillariae Uninbracteatae or Fritillaria wabuensis processes, the Bulbus Fritillariae Cirrhosae that is, " Chinese Pharmacopoeia " (version in 2015) is recorded.
The pharmaceutically acceptable adjuvant being previously mentioned in the present invention, including " medicinal excipient handbook " (American Pharmaceutical Association,
In October, 1986), Chemical Industry Press publish " pharmaceutic adjuvant handbook " (handbook of pharmaceutical
Excipients, original work fourth edition) or " pharmaceutical necessitieses are complete works of " (Sichuan Publishing Group, Sichuan science tech publishing house publish,
In January, 2006) listed by adjuvant, but be not limited to these adjuvants.
Compared with prior art, the method have the advantages that
(1) present invention selects natto lyophilized powder, oligomeric xylose and Bulbus Fritillariae Cirrhosae as crude drug, by scientific composition, presses one
Fixed weight proportion composition.Three's compatibility uses, and increases the immunity of human body from different perspectives, reduces body weight, reduces fat mass.
Prove through animal experiment, strengthen immunity, the effect of lipid-loweringing loss of weight clearly.
(2) natto lyophilized powder in the present invention, oligomeric xylose and Bulbus Fritillariae Cirrhosae have long-term edible history, and safety is good
Good.
(3) present invention selects oligomeric xylose as crude drug, does not hydrolyze the enzyme of oligomeric xylose, take in human gastrointestinal tract
After be directly entered big enteral and be preferably bacillus bifiduss and utilized, it is to avoid directly take probiotic bacteria, stomach enteral be inactivated and not
The shortcoming that can play a role.Using natto lyophilized powder as raw material, natto lyophilized powder is the natto of solid fermentation, dry through freezing
Dry, pulverizing, becomes natto lyophilized powder, remains the biological active substanceies in natto to greatest extent it is ensured that the present invention loses weight
Effect with enhancing immunity.
(4) present invention, according to the characteristic of crude drug, using scientific and rational preparation method, Bulbus Fritillariae Cirrhosae is beaten and is used as medicine after powder,
Remain effective ingredient to greatest extent, prepare safely and effectively preparation so as to take effect more stable, controlled.
(5) present invention employs oral formulations, conveniently produce, store, transport, carry and take.
Brief description
Fig. 1 is tablet manufacturing process chart.
Specific embodiment
Embodiment 1
Composition: natto lyophilized powder 200g, oligomeric xylose 200g, Bulbus Fritillariae Cirrhosae 100g, Microcrystalline Cellulose 100g, magnesium stearate
5g, silicon dioxide 5g.
Preparation method: weigh the supplementary material of formula ratio, Bulbus Fritillariae Cirrhosae was pulverized 80 mesh sieves, obtain Bulbus Fritillariae Cirrhosae fine powder；By natto
Lyophilized powder, oligomeric xylose cross 80 mesh sieves respectively, obtain natto lyophilized powder fine powder and oligomeric xylose fine powder；By Microcrystalline Cellulose, Hard Fat
Sour magnesium, silicon dioxide cross 80 mesh sieves respectively, standby；By Bulbus Fritillariae Cirrhosae fine powder, natto lyophilized powder fine powder, oligomeric xylose fine powder and sieve
Microcrystalline Cellulose afterwards, magnesium stearate, silicon dioxide mix homogeneously, tabletting, prepared tablet.
Embodiment 2
Composition: natto lyophilized powder 110g, oligomeric xylose 120g, Bulbus Fritillariae Cirrhosae 150g, Microcrystalline Cellulose 100g, magnesium stearate
5g, silicon dioxide 8g.
Preparation method: weigh the supplementary material of formula ratio, Bulbus Fritillariae Cirrhosae was pulverized 80 mesh sieves, obtain Bulbus Fritillariae Cirrhosae fine powder；By natto
Lyophilized powder, oligomeric xylose cross 80 mesh sieves respectively, obtain natto lyophilized powder fine powder and oligomeric xylose fine powder；By Microcrystalline Cellulose, Hard Fat
Sour magnesium, silicon dioxide cross 80 mesh sieves respectively, standby；By Bulbus Fritillariae Cirrhosae fine powder, natto lyophilized powder fine powder, oligomeric xylose fine powder and sieve
Microcrystalline Cellulose afterwards, magnesium stearate, silicon dioxide mix homogeneously, tabletting, prepared tablet.
Embodiment 3
Composition: natto lyophilized powder 150g, oligomeric xylose 240g, Bulbus Fritillariae Cirrhosae 120g, Microcrystalline Cellulose 70g, magnesium stearate 4g,
Silicon dioxide 6g.
Preparation method: weigh the supplementary material of formula ratio, Bulbus Fritillariae Cirrhosae was pulverized 80 mesh sieves, obtain Bulbus Fritillariae Cirrhosae fine powder；By natto
Lyophilized powder, oligomeric xylose cross 80 mesh sieves respectively, obtain natto lyophilized powder fine powder and oligomeric xylose fine powder；By Microcrystalline Cellulose, Hard Fat
Sour magnesium, silicon dioxide cross 80 mesh sieves respectively, standby；By Bulbus Fritillariae Cirrhosae fine powder, natto lyophilized powder fine powder, oligomeric xylose fine powder and sieve
Microcrystalline Cellulose afterwards, magnesium stearate, silicon dioxide mix homogeneously, tabletting, prepared tablet.
Embodiment 4
Composition: natto lyophilized powder 300g, oligomeric xylose 200g, Bulbus Fritillariae Cirrhosae 60g, Microcrystalline Cellulose 110g, magnesium stearate 6g,
Silicon dioxide 9g.
Preparation method: weigh the supplementary material of formula ratio, Bulbus Fritillariae Cirrhosae was pulverized 80 mesh sieves, obtain Bulbus Fritillariae Cirrhosae fine powder；By natto
Lyophilized powder, oligomeric xylose cross 80 mesh sieves respectively, obtain natto lyophilized powder fine powder and oligomeric xylose fine powder；By Microcrystalline Cellulose, Hard Fat
Sour magnesium, silicon dioxide cross 80 mesh sieves respectively, standby；By Bulbus Fritillariae Cirrhosae fine powder, natto lyophilized powder fine powder, oligomeric xylose fine powder and sieve
Microcrystalline Cellulose afterwards, magnesium stearate, silicon dioxide mix homogeneously, tabletting, prepared tablet.
Embodiment 5
Composition: natto lyophilized powder 220g, oligomeric xylose 130g, Bulbus Fritillariae Cirrhosae 80g, Microcrystalline Cellulose 90g, magnesium stearate 5g,
Silicon dioxide 7g.
Preparation method: weigh the supplementary material of formula ratio, Bulbus Fritillariae Cirrhosae was pulverized 80 mesh sieves, obtain Bulbus Fritillariae Cirrhosae fine powder；By natto
Lyophilized powder, oligomeric xylose cross 80 mesh sieves respectively, obtain natto lyophilized powder fine powder and oligomeric xylose fine powder；By Microcrystalline Cellulose, Hard Fat
Sour magnesium, silicon dioxide cross 80 mesh sieves respectively, standby；By Bulbus Fritillariae Cirrhosae fine powder, natto lyophilized powder fine powder, oligomeric xylose fine powder and sieve
Microcrystalline Cellulose afterwards, magnesium stearate, silicon dioxide mix homogeneously, tabletting, prepared tablet.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all essences in the present invention
Any modification, equivalent and improvement made within god and principle etc., should be included within the scope of the present invention.
Pharmacodynamics experiment and result to the carrying out of the present invention are as follows.
First, enhancing immunity experiment
(1) by reagent
Invention formulation 1: be prepared into tablet by embodiment 1, dilute makes suspension；
Invention formulation 2: be prepared into tablet by embodiment 2, dilute makes suspension；
Invention formulation 3: be prepared into tablet by embodiment 3, dilute makes suspension；
Invention formulation 4: be prepared into tablet by embodiment 4, dilute makes suspension；
Invention formulation 5: be prepared into tablet by embodiment 5, dilute makes suspension；
Negative control: distilled water.
(2) experimental animal: Kunming mouse, gynoecy, body weight 18-22g, dynamic by Chengdu Inst. of Biological Products's experiment
Thing center provides.
(3) test data adopts spss 10.0 for windows software kit to process.Matched group and the data of dosage group
Through homogeneity test of variance, variance is neat, carries out variance analyses, and such as p value is less than 0.05, then compared two-by-two with dunnett method；If
Heterogeneity of variance, then carry out data conversion, still uneven, uses rank test instead, and such as p value is less than 0.05, then use dunnett's t3 method
Compared two-by-two.
(4) test method and result
The impact of 1 pair of mouse humoral immune
The impact of 1.1 pairs of mouse antibodies cellulations
1.1.1 test method: antibody-producting cell detection (jerne improves slide method)
Every mouse peritoneal injection 2% hematocrit srbc0.2ml, the mice cervical dislocation after immune 5 days is put to death, takes out spleen
Dirty be placed in the plate filling hank ' s, grind spleen, make cell suspension, through 200 mesh sieve net filtrations, be centrifuged (1000r/
Min) 10min, is washed 2 times with hank ' s liquid, finally by cell suspension in 5mlrpmi1640 culture fluid, platform phenol orchid dyeing counting
(should be more than 95%), and cell concentration is adjusted to 5 × 106Individual/ml, makes splenocyte suspension.Agarose is configured to 1%
Aqueous solution, water-bath is boiled 30 minutes, concentration hank double with equivalent ' s liquid mixes, subpackage small test tube, often pipe 0.5ml, then into pipe
(using sa buffer) hematocrit srbc 50 μ l of plus 10%, each 20 μ l of splenocyte suspension do two Duplicate Samples, rapid mix after,
It is poured on agarose thin layer slide, after agar solidification, slide level is buckled and is placed on horse, put into CO2 gas incubator
Middle incubation 1.5h, then complement is added in glass frame groove, continues to incubate 1.5h, counts hemolysis plaque number.Prepared by complement
It is collection guinea pig blood, isolate serum (pooled serums of at least 5 Cavia porcelluss), 1ml hematocrit srbc is added to 5ml guinea pig serum
In, 30min placed by 4 DEG C of refrigerators, often vibrates, centrifuging and taking supernatant, subpackage, -70 DEG C of preservations.Used time with sa buffer press 1:
1.5 dilution.
1.1.2 result of the test, is shown in Table 1.
The impact to mouse antibodies cellulation for the table 1
From table 1, continuous gavage is after 30 days, the hemolysis plaque number of 1～5 group of animal of invention formulation and negative control group
Compare, be statistically analyzed, all have significant difference (p < 0.05).
The impact of 1.2 pairs of mice serum hemolysins
1.2.1 test method: serum hemolysin measures (Hemagglutination Method)
Every mouse peritoneal injection 2%srbc0.2ml immunity, continued gavage after 5 days, extracts eyeball and takes blood in centrifuge tube
Interior, place 1 hour, peel off, 2000r/min is centrifuged 10 minutes, collect serum, with normal saline, serum is made doubling dilution, often
Part dilution 12 holes, different dilution serum are placed in blood-coagulation-board, every hole 100 μ l, add 0.5%srbc suspension 100 μ l,
Mix, put 37 DEG C of wet box observed result after 3 hours, record the coagulation degree in every hole.Calculating antibody product.
1.2.2 result of the test, is shown in Table 2.
The impact to mice serum hemolysin for the table 2
As shown in Table 2, continuous gavage is after 30 days, the antibody product of 1～5 group of animal of invention formulation and negative control group phase
Ratio is statistically analyzed, all has significant difference (p < 0.05).
1.3 conclusion
Table 1, the result of table 2 show, the present invention is positive to mouse humoral immune result of the test.
The impact of 2 pairs of Murine Nk Activities
2.1 test methods: nk cytoactive detection (lactic acid dehydrogenase ldh algoscopy)
Cervical dislocation puts to death animal, takes out spleen, tears up, and after crossing 200 eye mesh screens, washes 3 times with hank ' s liquid, every time
1000r/min is centrifuged 10min, takes cytoplasm, aquesterilisa splitting erythrocyte, platform phenol orchid dyeing counting (should be more than 95%), uses
RPMI-1640 completely is made into 2x107Individual/ml cell suspension.By the cell suspension of each mice take 300 μ l be placed in 96 holes training
In foster plate, every hole 100 μ l, every hole adds target cell (yac-1 cell, 4x105Individual/m) 100 μ l, do target cell Spontaneous release simultaneously
Hole (target cell 100 μ l, culture fluid 100 μ l) and maximum release aperture (target cell 100 μ+2.5%triton 100 μ l) each 3 holes, 37
DEG C 5%co2Culture 4 hours, takes out 1500r/min centrifugation 5min.Each hole supernatant 100 μ l is placed in another culture plate, often
Hole adds 100 μ l substrate, adds 1mol/lhcl30 μ l terminating reaction after 10 minutes, measures od value at 490nm, calculates nk cell
Activity rate.
2.2 result of the tests, are shown in Table 3.
The impact to Murine Nk Activity for the table 3
From table 3, continuous gavage is after 30 days, the nk cytoactive of 1～5 group of animal of invention formulation and negative control group
Compare, be statistically analyzed, all have significant difference (p < 0.05).
2.3 conclusion
The result of table 3 shows, the present invention is positive to Murine Nk Activity result of the test.
The impact of 3 pairs of mouse monokaryon-macrophage phagocytic functions
3.1 pairs of mouse macrophages swallow the impact of chicken red blood cell ability
3.1.1 test method: Turnover of Mouse Peritoneal Macrophages phagocytosis chicken red blood cell test (half intracorporal method)
After continuous gavage 30 days, every mouse peritoneal injection 20% chicken erythrocyte suspension 1ml, after 30 points of kinds, cervical dislocation
Put to death, be fixed on Mus plate, abdominal skin is cut off in center, through abdominal cavity saline injection 2ml, rotate Mus plate 1 minute, inhale
Go out abdominal cavity washing liquid 1ml, mean droplet, on 2 microscope slides, puts 37 DEG C of wet box 30 minutes, take out and rinse, dry, consolidating in normal saline
Fixed, 4%giemsapbs dyes 3 minutes, and distilled water rinses airing, microscopy.Calculate phagocytic percentage and phagocytic index.
3.1.2 result of the test: be shown in Table 4.
Table 4 swallows the impact of chicken red blood cell ability to mouse macrophage
From table 4, after 30 days, the phagocytic rate of 1～5 group of animal of invention formulation and phagocytic index are all obvious for continuous gavage
Raise, compared with negative control group, have significant difference (p < 0.05).
The impact of 3.2 pairs of mouse monokaryon-macrophage carbonic clearance functions
3.2.1 test method: mouse carbonic clearance test
After continuous gavage 30 days, in the mouse tail vein injection india ink of 4 times of normal saline dilutions, by 0.1ml/
Timing immediately after the injection of 10g prepared Chinese ink, after injection prepared Chinese ink, the 2nd, 10min takes blood 20 μ l respectively at angular vein, is added to 2ml
na2co3Solution makees blank, measures optical density value with 723 spectrophotometers at 600nm.Take sacrifice after blood, take
Liver, spleen are weighed, and calculate phagocytic index.
The impact to mouse monokaryon-macrophage carbonic clearance function for the table 5
It can be seen that, after 30 days, the carbonic clearance ability of 1～5 group of animal of invention formulation is compared with negative control group for continuous gavage
More all there is significant difference (p < 0.05).
3.3 conclusion
Shown by the result of table 4, table 5, the present invention is in sun to the monocytes/macrophages phagocytic function test result of mice
Property.
To sum up, the present invention is positive to mouse humoral immune result of the test, is in sun to Murine Nk Activity result of the test
Property, the monocytes/macrophages phagocytic function test result of mice is positive.The present invention has the effect of enhancing immunity.
2nd, antiobesity action experiment
(1) by reagent:
Invention formulation 1: be prepared into tablet by embodiment 1, add water and make suspension.
Invention formulation 2: be prepared into tablet by embodiment 2, add water and make suspension.
Invention formulation 3: be prepared into tablet by embodiment 3, add water and make suspension.
Invention formulation 4: be prepared into tablet by embodiment 4, add water and make suspension.
Invention formulation 5: be prepared into tablet by embodiment 5, add water and make suspension.
Negative control: normal saline.
(2) experimental animal: Male Wistar Rats, body weight about 220 ± 10g, dynamic by Sichuan Academy of Medical Sciences's experiment
Thing institute provides.
(3) test data adopts spss 10.0 for windows software kit to process.Matched group and the data of dosage group
Through homogeneity test of variance, variance is neat, carries out variance analyses, and such as p value is less than 0.05, then compared two-by-two with dunnett method；If
Heterogeneity of variance, then carry out data conversion, still uneven, uses rank test instead, and such as p value is less than 0.05, then use dunnett's t3 method
Compared two-by-two.
(4) test method and result
1. set up Diet-induced obesity rat model:
Feed rat with nutrient fodder 45 days, compared with the rat of the same age fed with standard full price mouse feed, body weight increase, have
Significant difference.Nutrient fodder is standard full price mouse feed 60%, Adeps Sus domestica 10%, sucrose 6%, milk powder 6%, Semen arachidis hypogaeae 5%, egg
10%th, Oleum Sesami 1%, Sal 2%.
2. continuous nursing 30 days, routine weighing, record food ration.Experiment terminates, and weighs, and puts to death rat, takes item under omoplate
Fat (brown fat) is weighed afterwards；Take kidney week Abdominal Wall Fat and epididymal adipose tissues (white adipose), represent internal fat with both sums
Fat amount.
3. result of the test shows, continuous gavage is after 30 days, 1～5 group of animal ingestion amount of invention formulation with to negative control
Group no significant difference.Impact to rat body weight and fat mass is shown in Table 6, table 7.
The impact to rat body weight for the table 6
From table 6, after 30 days, 1～5 group of the weight of animals of invention formulation substantially reduces, with negative control continuous gavage
Group compares, and has significant difference (p < 0.05).
The impact to rat fat amount for the table 7
From table 7, after 30 days, 1～5 group of Animal fat amount of invention formulation is compared with negative control group for continuous gavage
Relatively, there is significant difference (p < 0.05).
4. conclusion
Shown by the result of table 7, table 8, the present invention is positive to the fat-reducing result of the test of rat.
In sum, the raw material of the present composition and weight proportion are: 10～30 parts of natto lyophilized powder, oligomeric xylose 10
～30 parts, 5～15 parts of Bulbus Fritillariae Cirrhosae, preferred feedstock and weight proportion be 15～25 parts of natto lyophilized powder, 10～20 parts of oligomeric xylose,
5～12 parts of Bulbus Fritillariae Cirrhosae, further preferred raw material and weight proportion be 17～22 parts of natto lyophilized powder, 13～19 parts of oligomeric xylose,
5～10 parts of Bulbus Fritillariae Cirrhosae, more preferred raw material and weight proportion are 18 parts of natto lyophilized powder, 18 parts of oligomeric xylose, 9 parts of Bulbus Fritillariae Cirrhosae.
The compositionss that the application present invention provides are respectively provided with fat-reducing and the effect of enhancing immunity.
Claims (10)
1. a kind of have fat-reducing and enhancing immunity effect compositionss it is characterised in that: the raw material of described compositionss and weight
Proportioning is: 10～30 parts of natto lyophilized powder, 10～30 parts of oligomeric xylose, 5～15 parts of Bulbus Fritillariae Cirrhosae.
2. according to claim 1 a kind of have fat-reducing and enhancing immunity effect compositionss it is characterised in that: described
The raw material of compositionss and weight proportion are: 15～25 parts of natto lyophilized powder, 10～20 parts of oligomeric xylose, 5～12 parts of Bulbus Fritillariae Cirrhosae.
3. according to claim 1 and 2 a kind of have fat-reducing and enhancing immunity effect compositionss it is characterised in that:
The raw material of described compositionss and weight proportion are: 17～22 parts of natto lyophilized powder, 13～19 parts of oligomeric xylose, Bulbus Fritillariae Cirrhosae 5～10
Part.
4. a kind of compositionss with fat-reducing and enhancing immunity effect according to any one of claims 1 to 3, its feature
It is: the raw material of described compositionss and weight proportion are: 18 parts of natto lyophilized powder, 18 parts of oligomeric xylose, 9 parts of Bulbus Fritillariae Cirrhosae.
5. a kind of compositionss with fat-reducing and enhancing immunity effect according to any one of Claims 1 to 4, its feature
It is: described compositionss are with natto lyophilized powder, oligomeric xylose and Bulbus Fritillariae Cirrhosae as crude drug, add pharmaceutically acceptable adjuvant
The preparation being conventionally prepared from.
6. a kind of compositionss with fat-reducing and enhancing immunity effect according to any one of Claims 1 to 5, its feature
It is: Bulbus Fritillariae Cirrhosae powder is broken into fine powder.
7. according to claim 5 a kind of have fat-reducing and enhancing immunity effect compositionss it is characterised in that: described
Preparation is oral formulations.
8. according to claim 7 a kind of have fat-reducing and enhancing immunity effect compositionss it is characterised in that: described
Oral formulations are granule, tablet, capsule.
9. the preparation of a kind of compositionss with fat-reducing and enhancing immunity effect according to any one of claim 1～8
Method it is characterised in that: comprise the steps:
(1) weigh raw material by weight；
(2) step (1) gained Bulbus Fritillariae Cirrhosae is pulverized and sieved, obtain Bulbus Fritillariae Cirrhosae fine powder；
(3) step (1) gained natto lyophilized powder, oligomeric xylose are sieved respectively, obtain natto lyophilized powder fine powder and oligomeric xylose is thin
Powder；
(4) 7～12 parts of Microcrystalline Cellulose, 0.1～0.5 part of magnesium stearate and 0.1～0.5 part of silicon dioxide, mistake respectively are weighed
Sieve, standby；
(5) by step (2) gained Bulbus Fritillariae Cirrhosae fine powder, step (3) gained natto lyophilized powder fine powder, oligomeric xylose fine powder and step
(4) gained Microcrystalline Cellulose, magnesium stearate and silicon dioxide, mix homogeneously, tabletting, prepared tablet.
10. a kind of described in any one of claim 1～8 has the compositionss of fat-reducing and enhancing immunity effect in preparation fat-reducing
With the purposes in the food of enhancing immunity, health product or medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610729715.XA CN106344784A (en) | 2016-08-26 | 2016-08-26 | Composition with functions of losing weight and enhancing immunity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610729715.XA CN106344784A (en) | 2016-08-26 | 2016-08-26 | Composition with functions of losing weight and enhancing immunity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106344784A true CN106344784A (en) | 2017-01-25 |
Family
ID=57854194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610729715.XA Pending CN106344784A (en) | 2016-08-26 | 2016-08-26 | Composition with functions of losing weight and enhancing immunity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106344784A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112715941A (en) * | 2021-01-29 | 2021-04-30 | 威海世纪博康海藻有限公司 | Composition capable of losing weight and enhancing immunity, product and application thereof |
| CN113261678A (en) * | 2021-04-15 | 2021-08-17 | 山东卫康生物医药科技有限公司 | Preparation process of natto xylooligosaccharide powder suitable for people with low immunity |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347529A (en) * | 2008-08-11 | 2009-01-21 | 朱子臣 | Compound dual-purpose natto capsules as medicine or food and preparation thereof |
| CN101606701A (en) * | 2009-07-20 | 2009-12-23 | 李雪萍 | Natto pollen preparation |
| CN103223033A (en) * | 2013-05-22 | 2013-07-31 | 武汉真福医药科技发展有限公司 | Novel natto health-care composite and preparation method and application thereof |
| CN104799286A (en) * | 2015-04-30 | 2015-07-29 | 南京中生生物科技有限公司 | Composition for improving immunity and preparation method of composition |
-
2016
- 2016-08-26 CN CN201610729715.XA patent/CN106344784A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101347529A (en) * | 2008-08-11 | 2009-01-21 | 朱子臣 | Compound dual-purpose natto capsules as medicine or food and preparation thereof |
| CN101606701A (en) * | 2009-07-20 | 2009-12-23 | 李雪萍 | Natto pollen preparation |
| CN103223033A (en) * | 2013-05-22 | 2013-07-31 | 武汉真福医药科技发展有限公司 | Novel natto health-care composite and preparation method and application thereof |
| CN104799286A (en) * | 2015-04-30 | 2015-07-29 | 南京中生生物科技有限公司 | Composition for improving immunity and preparation method of composition |
Non-Patent Citations (1)
| Title |
|---|
| 东方财富网: "北京世纪合辉医药科技股份有限公司公开转让说明书（申报稿）", 《HTTP://WAP.EASTMONEY.COM/3G/REPORT/ARTICLE,REPORT,20140915,2WVL2UICSYYUCF_1000.SHTML》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112715941A (en) * | 2021-01-29 | 2021-04-30 | 威海世纪博康海藻有限公司 | Composition capable of losing weight and enhancing immunity, product and application thereof |
| CN113261678A (en) * | 2021-04-15 | 2021-08-17 | 山东卫康生物医药科技有限公司 | Preparation process of natto xylooligosaccharide powder suitable for people with low immunity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100487064C (en) | Preparation process of squid ink black pigment and application thereof | |
| WO2017124921A1 (en) | Walnut oligopeptide powder, and preparation method and application thereof | |
| CN101940313B (en) | Health food capable of enhancing immunity of human body and preparation method thereof | |
| CN106820151A (en) | A kind of bivalve compound health composition, preparation method and application | |
| CN109528814A (en) | A kind of probiotics and its preparation method and application of lactobacillus-fermented Radix Astragali | |
| CN108902628A (en) | A kind of anti-inflammatory probiotics solid beverage of children | |
| CN103976359B (en) | Food nutrient fortifying composition and application, health food and preparation method thereof | |
| CN103169737A (en) | Composite of Antrodia camphorata entity and shell-broken ganoderma lucidum spore powder and application thereof in immune adjustment | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN106344784A (en) | Composition with functions of losing weight and enhancing immunity and preparation method thereof | |
| CN103584091B (en) | A kind of guarantor with raising immunity, hypolipemic function builds food and preparation method thereof | |
| CN102860496B (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
| CN103735621B (en) | A kind of Chinese medicine composition with blood fat reducing and enhancing immunity effect | |
| CN104288344A (en) | Applications of a Pu'er tea extract product in preparation of medicines or foods adjusting intestinal flora and relaxing the bowels | |
| CN106361842A (en) | Anti-fatigue healthcare capsules | |
| CN107951992A (en) | A kind of Chinese medicine composition for strengthen immunity and preparation method thereof | |
| CN108057049A (en) | A kind of Chinese medicine composition for enhancing cell viability and preparation method thereof | |
| CN101559073A (en) | Cordyceps and ganoderma lucidum polysaccharides compound preparation with immune synergism | |
| CN104189038B (en) | Chinese medicine preparation for nursing one's health female pathology health and immunologic function | |
| CN104286844A (en) | Food, health product or medicine composition capable of improving immunity | |
| CN112870234A (en) | Application of pharmaceutical composition containing chlorogenic acid in preparation of medicines for treating pathological jaundice | |
| CN102406172B (en) | Health-care food for enhancing immunity and preparation method thereof | |
| CN106728962B (en) | Pharmaceutical composition for enhancing immunity and application thereof | |
| CN113116938A (en) | Quadruple viable bacteria preparation and application thereof | |
| CN104906146B (en) | Medical applications of the peacilomyce hepiahi bacterium strain PH40 in depression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170125 |
|
| RJ01 | Rejection of invention patent application after publication |